Novel Discovery of the Relationship of Clinical Phenotype of Coronary Heart Disease with Retinol Binding Protein 4, Lipoprotein-Related Phospholipase A2
Clinical Medicine Research
Volume 6, Issue 4, July 2017, Pages: 131-134
Received: May 2, 2017;
Accepted: May 18, 2017;
Published: Jun. 29, 2017
Views 2273 Downloads 97
Liu-qiang Lv, Department of Cardiovascular Medicine, Huaibei People’s Hospital, Huaibei, China
Yang-zhang Tang, Department of Cardiovascular Medicine, Huaibei People’s Hospital, Huaibei, China
Shi-qiang Wang, Department of Cardiovascular Medicine, Huaibei People’s Hospital, Huaibei, China
Gui Ren, Department of Bioengineering, Northwestern Polytechnic University, Fremont, USA
Yu-Chen Lo, Department of Bioengineering, Stanford University, Palo Alto, USA
Hiroshi Honda, Department of Bioengineering, Northwestern Polytechnic University, Fremont, USA
Edward J. Parish, Department of Chemistry, Auburn University, Auburn, USA
Follow on us
To investigate the correlation between retinol binding protein 4 (RBP4), lipoprotein associated phospholipase A2 (LP-PLA2), we studied the clinical phenotype of coronary heart disease (CHD) and the severity of coronary artery disease. Our studies showed that the changes of retinol binding protein 4, LP-PLA2 serum concentration has a relation with the severity of coronary artery disease progression, but no clear relationship with the degree of coronary artery lesion and count. Furthermore, LP-PLA2 concentration increases with the increase of the severity of coronary artery disease and disease occurrences.
Retinol Binding Protein 4, Lipoprotein Associated Phospholipase A2, Coronary Heart Disease, Coronary Artery Lesion Degree
To cite this article
Edward J. Parish,
Novel Discovery of the Relationship of Clinical Phenotype of Coronary Heart Disease with Retinol Binding Protein 4, Lipoprotein-Related Phospholipase A2, Clinical Medicine Research.
Vol. 6, No. 4,
2017, pp. 131-134.
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Guo Jifang, Kong Fanhe. Retinol binding protein 4 and coronary heart disease correlation. Mudanjiang Medical College, 2013, 34: 12-14.
Maiolino G, Pedon L, Cesari M, et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high rick coronary artery disease patients. PLOS One, 2012, 7(10): e48171.
Han Yaling. Chang'an International Cardiovascular Forum. Chinese percutaneous coronary intervention guidelines. Chinese Journal of Cardiology, 2012, 40 (4): 252-254.
Li F, Xia K, Sheikh MS, et al. Retinol binding protein 4 promotes hyperinsulinism-induced proliferation of rat aortic smooth muscle cells, Mol Med Rep, 2014, 9 (5): 1634-1640.
Ge Ling, Cheng Xunmin, YANG Song, et al. Retinol binding protein 4 and lipoprotein-associated phospholipase A2 levels and coronary heart disease and coronary artery disease characteristics of the correlation analysis. Bengbu Medical College, 40 (8): 1102-1104.
Fortunato J, Bláha V, Bis J, et al. Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus. J Diabetes Res, 2014, 2014: 278063.
Caslake M J, Packard C J. Lipoprotein –associated phospholipase A2 (platelet-activating factoracetylhydrolase) and cardiovascular disease. Curr Opin Lipidol, 2003, 14 (4): 347-352.
Zhao Yong, Guo Zhibin. The value of lipoprotein-associated phospholipase A2 in predicting the risk of coronary heart disease. Journal of Applied Clinical Medicine, 2014, 15 (12): 1-3.
Ferguson J F, Hinkle CC, Mehta NN, et al. Translational studies of lipoprotein-associated phospholipase A2 in inflammation and atherosclerosis. J AM Coll Cardiol, 2012, 59 (8): 764-772.
Liu Hai-liang, Li Guo-qing. Relationship between serum retinol-binding protein-4 and high-sensitivity C-reactive protein in patients with coronary heart disease. Journal of Clinical Internal Medicine, 2011, 28 (2): 92-94.
Liu Xingjia, Zheng Xing, Qin Yongwen, et al. Lipoprotein-related phospholipase A2 activity in response to coronary angiography sclerosis degree, Journal of the Second Military Medical University, 2006, 27: 391-395.
Cai A, Li G, Chen J, et al. Increased serum level of LP-PLA2 is independentiy associatated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. BMC Cardiovasc Disord, 2015, 15 (1): 14.
Wang Lili, Lei Changcheng. Lipoprotein-related phospholipase A2 and coronary heart disease related research progress. Modern Medicine and Health, 2015, 31 (1): 57-60.
Pan Chen-liang, Peng Yu, Hu Xue-ting, et al. Correlation between lipoprotein-associated phospholipase A2 and acute syndromes. Clinical Cardiovascular Diseases, 2014, 30 (11): 962-965.
Kolodgie F D, Burke A P, Skorija K S, et al. Lipoprotein –associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 2006, 26: 2523-2529.